Celltrion to contract biological product supply with BMS

Bristol-Myer Squibb (BMS), an American gigantic pharmaceutical company, and Celltrion, a Korea bio venture company, signed an agreement on June 22 covering the production and supply of biological products to BMS for 10 years, which estimated about to the total U$2 billion.

Mr. C de Notaristefany, president of BMS technology project said "our core strategy for the biological product business...